Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Helus PharmaSTU:R7E +2.73%38 Market Cap is €392.26 Mil as of Jul. 18, 2026. GuruFocus rates STU:R7E with a GF Score™ of 38/100. The stock has 2 warning signs investors should review. Among 1,423 Biotechnology companies, Helus Pharma ranks better than 69.78% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Helus Pharma's share price for the quarter that ended in Mar. 2026 was €4.12. Helus Pharma's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 51.63 Mil. Therefore, Helus Pharma's market cap for the quarter that ended in Mar. 2026 was €212.72 Mil.
Helus Pharma's quarterly market cap
increased
from Sep. 2025 (€131.81 Mil) to Dec. 2025 (€366.72 Mil) but then
declined
from Dec. 2025 (€366.72 Mil) to Mar. 2026 (€212.72 Mil).
Helus Pharma's annual market cap
declined
from Mar. 2024 (€282.75 Mil) to Mar. 2025 (€125.34 Mil) but then
increased
from Mar. 2025 (€125.34 Mil) to Mar. 2026 (€212.72 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Helus Pharma's Enterprise Value for Today is €344.09 Mil.
Helus Pharma (STU:R7E) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Helus Pharma Market Cap Related Terms
Helus Pharma Market Cap Historical Data
* Premium members only.
The historical data trend for Helus Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:R7E vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Helus Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Helus Pharma Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Helus Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Helus Pharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Helus Pharma's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Helus Pharma (STU:R7E) has a Market Cap of €392.26 Mil as of Jul. 18, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Helus Pharma and its competitors. According to the industry distribution chart, Helus Pharma ranks #430 out of 1423 companies in the Biotechnology industry, placing it in the top 30.2%.
Is Helus Pharma's Market Cap too high?
Helus Pharma's current Market Cap is €392.26 Mil. Based on the distribution chart, Helus Pharma ranks #430 out of 1423 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Helus Pharma has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Helus Pharma's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Helus Pharma ranks #430 out of 1423 companies for Market Cap. This puts Helus Pharma in the upper half of its industry. The industry median Market Cap is 113.78. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.78, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Helus Pharma and its competitors. For the Biotechnology industry, the median Market Cap is 113.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Helus Pharma's current Market Cap is €392.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helus Pharma stock overvalued right now?
Helus Pharma (STU:R7E) has a current Market Cap of €392.26 Mil. The current Market Cap is €392.26 Mil. Helus Pharma's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Helus Pharma (STU:R7E), the current Market Cap is €392.26 Mil as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
38GF Score
Get the complete analysis for STU:R7E
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:R7E has been successfully added to your 
